Lymphoblast transcriptome analysis in 22q11.2 deletion syndrome individuals with schizophrenia-spectrum disorder
Conclusions: Candidate pathways and upstream regulators may serve as novel biomarkers and treatment targets for SZ. Future transcriptome studies, including larger samples and proteomic analysis, are needed to substantiate our findings.PMID:38493364 | DOI:10.1080/15622975.2024.2327030
Source: The World Journal of Biological Psychiatry - Category: Psychiatry Authors: Elena Michaelovsky Miri Carmel Doron Gothelf Abraham Weizman Source Type: research
More News: Brain | Genetics | Microdeletion Syndromes | Neurology | Psychiatry | Schizophrenia | Study | Women